Acalabrutinib patient study for early access CLL in the UK
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL (or sometimes small lymphocytic lymphoma, SLL).
- You did not take acalabrutinib before (you started it for the first time).
- You started acalabrutinib through the UK Early Access Programme (not routine care).
- Your first dose was between April 1, 2020 and April 1, 2021.
- You are 18 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This study looks at how acalabrutinib works in real-world everyday medical practice for people with MCL or CLL who have already had at least one prior treatment. The goal is to see how well the drug performs outside of a strict research setting.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
Hear when a new Chronic Lymphocytic Leukemia, CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.